5 unchanged sentences
This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.
+Added: Stock Price Performance Graph
+Added: This graph shall not be deemed “soliciting material” or be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any of our filings under the Securities Act whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.
+Added: The following stock performance graph compares our total stock return with the total return for (i) the Nasdaq Composite Index and the (ii) the Nasdaq Biotechnology Index for the period from December 31, 2020 through December 31, 2025.
+Added: The figures represented below assume an investment of $100 in our common stock at the closing price of $196.75 on December 31, 2020 and in the Nasdaq Composite Index and the Nasdaq Biotechnology Index on December 31, 2020 and the reinvestment of dividends into shares of common stock.
+Added: The comparisons in the table are required by the SEC and are not intended to forecast or be indicative of possible future performance of our common stock.
+Added: During 2023, the Company completed a reverse merger, which brought in an entirely new pipeline of product candidates targeting IBD, and refreshed the Board and executive team to lead development of this new pipeline and sunset legacy asset development.
+Added: Additionally, the Company has since expanded its pipeline into RD.
+Added: The graph below includes pre-reverse merger stock performance, which is not relevant to Spyre's current stock performance.
+Added: Company/Index 2020 2021 2022 2023 2024 2025
+Added: Spyre Therapeutics, Inc.
+Added: (SYRE) $ 100.00 $ 60.36 $ 5.72 $ 10.94 $ 11.83 $ 16.65
+Added: NASDAQ Biotechnology $ 100.00 $ 100.02 $ 89.90 $ 94.03 $ 93.49 $ 124.75
+Added: Nasdaq Composite Index $ 100.00 $ 122.18 $ 82.43 $ 119.22 $ 154.48 $ 187.14
We have never declared or paid any cash dividends on our capital stock.
2 unchanged sentences
Recent Sales of Unregistered Securities
−Removed: On December 31, 2024, in accordance with the Paragon Agreement and to settle the Company’s 2024 obligations under the Parapyre Option Obligation (as defined below), we issued to Parapyre a warrant to purchase an aggregate of up to 848,184 shares of our common stock, with a per share exercise price equal to $23.28, which was the closing price of a share of the Company's common stock on December 31, 2024 (the “Issue Date”), the last business day of the calendar year-ended December 31, 2024, effective as of the Issue Date and an expiration date of the 10th anniversary of the Issue Date.
−Removed: We have relied on the exemption from registration requirements provided by Section 4(a)(2) under the Securities Act of 1933, as amended, relating to a transaction not involving any public offering to a single accredited investor.
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.